New trial aims to stop CMV eye inflammation from returning
NCT ID NCT07513623
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether oral valganciclovir or ganciclovir eye drops can reduce the virus causing eye inflammation and prevent flare-ups. About 117 adults with CMV anterior uveitis will receive either antiviral treatment or placebo for 7 days, then some continue for 12 months. The goal is to find a better way to control the infection and keep the disease from coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Valganciclovir (oral) and ganciclovir (eye drops)
What this could lead to
If successful, this could provide effective antiviral strategies to control CMV eye inflammation and reduce the risk of it coming back.
What could go wrong
This is an early phase 2 trial with a small number of participants. The treatments may not work better than placebo, and side effects from antiviral drugs are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS (CMV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chang Gung University
Taoyuan, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chiang Mai University
Chiang Mai, Thailand
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chulalongkorn University
Bangkok, Thailand
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Khon Kaen University
Khon Kaen, Thailand
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Proctor Foundation, University of California San Francisco
San Francisco, California, 94158, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Stein Eye Institute, University of California Los Angeles
Los Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••